文献速递传染病防控与疫情报告免疫规划

冻干人用狂犬病疫苗(Vero细胞)在9~65岁健康人群中的安全性与免疫原性

[Safety and immunogenicity of freeze-dried rabies vaccine (Vero-cells) for human use in healthy people aged 9-65 years].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2023-01-01

2015年3月在河南省登封市和泌阳县纳入1 956名9~65岁健康人,按1∶1∶1随机分为5剂对照组、4剂试验组和5剂试验组,每组652名。4剂试验组和5剂试验组不良反应发生率均低于5剂对照组(P<0.05),三组抗体阳转率均达100%,抗体GMC差异无统计学意义(均P>0.05)。

要点

  • 4剂试验组不良反应发生率35.43%(231/652)低于5剂对照组41.87%(273/652)(P<0.05)。
  • 5剂试验组不良反应发生率34.97%(228/652)低于5剂对照组41.87%(273/652)(P<0.05)。
  • 三组首针免后14 d和全程免后14 d抗体阳转率均为100%,各时点GMC差异均无统计学意义(均P>0.05)。

核心结论

  • 该冻干人用狂犬病疫苗(Vero细胞)按照5剂免疫程序和4剂免疫程序接种具有良好的安全性和免疫原性。

研究设计与样本

  • 采用随机、盲法、同类疫苗阳性对照的试验设计开展临床研究,于2015年3月在河南省登封市和泌阳县招募9~65岁健康人群为研究对象。
  • 共纳入1 956名受试者,按1∶1∶1随机分配至5剂对照组、4剂试验组和5剂试验组,每组652名。
  • 5剂对照组按照0、3、7、14、28 d免疫程序接种对照疫苗,4剂试验组按照0、7、21 d免疫程序(2-1-1程序)接种试验疫苗,5剂试验组按照0、3、7、14、28 d免疫程序接种试验疫苗。
  • 采用定期随访和主动报告相结合的方式,观察首针疫苗接种至全程疫苗接种后30 d局部和全身不良反应。
  • 于免疫前、首针接种后7 d、首针接种后14 d和全程接种后14 d采集静脉血,通过快速荧光灶抑制试验检测狂犬病病毒中和抗体,计算血清抗体阳转率和抗体几何平均浓度(GMC)。

主要发现

  • 5剂对照组、4剂试验组、5剂试验组不良反应发生率分别为41.87%(273/652)、35.43%(231/652)、34.97%(228/652),4剂试验组和5剂试验组不良反应发生率均低于5剂对照组(P<0.05)。
  • 局部不良反应主要为接种部位疼痛、瘙痒、肿胀和发红;全身不良反应主要为发热、乏力、头痛和肌肉痛。
  • 不良反应的严重程度均以轻度(1级)为主,分别占各组不良反应总例次数的85.33%(518/607)、89.02%(373/419)和88.96%(427/480)。
  • 三组的首针免后14 d和全程免后14 d抗体阳转率均为100%。
  • 在首针免后7、14 d和全程免后14 d,三组抗体GMC分别为0.60、0.72、0.59 IU/ml,20.42、23.99、24.38 IU/ml和22.95、23.52、24.72 IU/ml,差异均无统计学意义(均P>0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To assess the safety and immunogenicity of freeze-dried rabies vaccine (Vero-cells) for human use on different immunization procedures in healthy people aged 9-65 years. Methods: A randomized, blind, positive-controlled clinical study was conducted in March 2015. The eligible residents aged 9-65 were recruited in Dengfeng city and Biyang County, Henan Province. A total of 1 956 subjects were enrolled. The subjects were randomly (1∶1∶1) assigned to 5-dose control group, 4-dose trial group and 5-dose trial group, with 652 subjects in each group. The subjects of 5-dose control group were immunized with control vaccine on days 0, 3, 7, 14 and 28. The subjects of 4-dose trial group were immunized with trial vaccine on days 0, 7 and 21 (2-1-1 phases) and the subjects of 5-dose trial group were immunized with trial vaccine on days 0, 3, 7, 14 and 28. A combination of regular follow-up and active reporting was used to observe local and systemic adverse reactions till 30 days after the first and full immunization, and the incidence rate of adverse reactions in three groups was analyzed and compared. The venous blood was collected before the first immunization, 7 days after the first immunization, 14 days after the first immunization and 14 days after the full immunization. The neutralizing antibody of rabies virus was detected by rapid fluorescent focus inhibition test (RFFIT), and the seropositive conversion rate and geometric mean concentration (GMC) of antibody were calculated. Results: The adverse reaction rates in 5-dose control group, 4-dose trial group and 5-dose trial group were 41.87% (273/652), 35.43% (231/652) and 34.97% (228/652), respectively. The adverse reaction rates of 4-dose trial group and 5-dose trial group were lower than those of the 5-dose control group (P<0.05). The local reactions were mainly pain, itching, swelling and redness in injection site, while the systemic reactions were mainly fever, fatigue, headache and muscle pain. The severity of adverse reactions was mainly mild (level 1), accounting for 85.33% (518/607), 89.02% (373/419) and 88.96% (427/480) of the total number of adverse reactions in each group. At 14 days after the first immunization and 14 days after the full immunization, the antibody positive conversion rates of three groups were all 100%. At 7 days, 14 days after the first immunization and 14 days after the full immunization, the GMCs of three groups were 0.60, 0.72, 0.59 IU/ml, 20.42, 23.99, 24.38 IU/ml and 22.95, 23.52, 24.72 IU/ml, respectively, with no significant difference (P>0.05). Conclusion: The freeze-dried rabies vaccine (Vero-cells) for human use has good safety and immunogenicity when inoculated according to 5-dose and 4-dose immunization procedures. 目的: 评价冻干人用狂犬病疫苗(Vero细胞)以不同免疫程序在9~65岁健康人群中的安全性和免疫原性。 方法: 采用随机、盲法、同类疫苗阳性对照的试验设计开展临床研究,于2015年3月,在河南省登封市和泌阳县招募9~65岁健康人群为研究对象。共纳入1 956名受试者,按1∶1∶1随机分配至5剂对照组、4剂试验组和5剂试验组,每组652名。5剂对照组按照0、3、7、14、28 d免疫程序接种对照疫苗,4剂试验组按照0、7、21 d免疫程序(2-1-1程序)接种试验疫苗,5剂试验组按照0、3、7、14、28 d免疫程序接种试验疫苗。采用定期随访和主动报告相结合的方式,观察首针疫苗接种至全程疫苗接种后30 d局部和全身不良反应,并分析比较三组不良反应发生率。于免疫前、首针接种后7 d、首针接种后14 d和全程接种后14 d采集静脉血,通过快速荧光灶抑制试验检测狂犬病病毒中和抗体,计算血清抗体阳转率和抗体几何平均浓度(GMC)。 结果: 5剂对照组、4剂试验组、5剂试验组不良反应发生率分别为41.87%(273/652)、35.43%(231/652)、34.97%(228/652),4剂试验组和5剂试验组不良反应发生率均低于5剂对照组(P<0.05)。局部不良反应主要为接种部位疼痛、瘙痒、肿胀和发红;全身不良反应主要为发热、乏力、头痛和肌肉痛;不良反应的严重程度均以轻度(1级)为主,分别占各组不良反应总例次数的85.33%(518/607)、89.02%(373/419)和88.96%(427/480)。三组的首针免后14 d和全程免后14 d抗体阳转率均为100%;在首针免后7、14 d和全程免后14 d,三组抗体GMC分别为0.60、0.72、0.59 IU/ml,20.42、23.99、24.38 IU/ml和22.95、23.52、24.72 IU/ml,差异均无统计学意义(均P>0.05)。 结论: 该冻干人用狂犬病疫苗(Vero细胞)按照5剂免疫程序和4剂免疫程序接种具有良好的安全性和免疫原性。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Huang LL, Xie ZQ, Zhang W, et al. [Safety and immunogenicity of freeze-dried rabies vaccine (Vero-cells) for human use in healthy people aged 9-65 years]. Zhonghua Yu Fang Yi Xue Za Zhi. 2023. PMID: 36797580. doi:10.3760/cma.j.cn112150-20220314-00235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。